Pharmaceutical Giants May and Baker have announced plans to build a new facility in Anambra state as part of their efforts to invest in the state’s economy and grow its local manufacturing capacity.
Patrick Ajah, the Managing Director and Chief Executive Officer of May and Baker, revealed this in a statement during the 2025 Annual conference of the Association of Community Pharmacists of Nigeria hosted in the Capital city of Awka.
Ajah said this while receiving the Governor of the state at the company’s stand during the event. He revealed that besides its current depot operation in the commercial city of Onitsha that the pharmaceutical company was planning on building a new facility in the same city.
The company’s Ceo reiterated that May and Baker is the first indigenous pharmaceutical company in Nigeria, reinstating its commitment to local innovation and manufacturing. He added that the company is deeply committed to producing quality drugs locally and developing products from Nigerian research.
Governor Soludo, in response, expressed satisfaction, saying he was impressed that the products on display were being manufactured in Nigeria by May and Baker in their Ota, Ogun Plant, with plans to set up a plant in Anambra.
Ajah also revealed the herbal drug production output of May and Baker through its independent research by Nigerian scientists on homegrown plants. The Managing Director pointed out various products, including Roveda, made from bitter leaf and developed by the Vice Chancellor of Benson Idahosa University, Prof. Ernest Izevbigie, and a host of others.
May & Baker Nigeria Plc reported a 2024 net profit of N1.62 billion, up 50% from N1.08 billion in 2023, despite a Q4 decline. Revenue grew 47% to N28.91 billion, driven by pharmaceutical sales.
